CoChat

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

Open access
Lyu, Aram, Fan, Zenghua, Clark, Matthew, Lea, Averey, Luong, Diamond, Setayesh, Ali, Starzinski, Alec, Wolters, Rachel, Arias-Badia, Marcel, Allaire, Kate, Wu, Kai, Gurunathan, Vibha, Valderrábano, Laura, Wei, Xiao X., Miller, Richard A., Van Allen, Eliezer M., Fong, Lawrence · 2025 · Nature
Cited by 189

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs)1,2, partly because there are immunosuppressive myeloid cells in tumours 3,4. However, the heterogeneity of myeloid cells has made them difficult to target, making blockade of the colony stimulating factor-1 receptor (CSF1R) clinically ineffective. Here we use single-cell profiling on patient biopsies across the disease continuum and find that a distinct population of tumour-associated macrophages with elevated levels of SPP1 transcripts (SPP1 hi-TAMs) becomes enriched with the progression of prostate cancer to mCRPC. In syngeneic mouse modelling, an analogous macrophage population suppresses CD8+ T cell activity in vitro and promotes ICI resistance in vivo. Furthermore, Spp1 hi-TAMs are not responsive to anti-CSF1R antibody treatment. Pathway analysis identifies adenosine signalling as a potential mechanism for SPP1 hi-TAM-mediated immunotherapeutic resistance. Indeed, pharmacological inhibition of adenosine A2A receptors (A2ARs) significantly reverses Spp1 hi-TAM-mediated immunosuppression in CD8+ T cells in vitro and enhances CRPC responsiveness to programmed cell death protein 1 (PD-1) blockade in vivo. Consistent with preclinical results, inhibition of A2ARs using ciforadenant in combination with programmed death 1 ligand 1 (PD-L1) blockade using atezolizumab induces clinical responses in patients with mCRPC. Moreover, inhibiting A2ARs results in a significant decrease in SPP1 hi-TAM abundance in CRPC, indicating that this pathway is involved in both induction and downstream immunosuppression. Collectively, these findings establish SPP1 hi-TAMs as key mediators of ICI resistance in mCRPC through adenosine signalling, emphasizing their importance as both a therapeutic target and a potential biomarker for predicting treatment efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-08290-3

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Metadata

Authors
Lyu, A., Fan, Z., Clark, M., Lea, A., Luong, D., Setayesh, A., Starzinski, A., Wolters, R., Arias-Badia, M., Allaire, K., Wu, K., Gurunathan, V., Valderrábano, L., Wei, X. X., Miller, R. A., Van Allen, E. M., & Fong, L.
Venue
Nature
Published
2024-12-04
Volume
637
Issue
8048
Pages
1207-1217
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4405029585
Cited by
189
References
19
FWCI
25.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. https://app.cochat.ai/papers/10.1038/s41586-024-08290-3
The paper
Lyu, A., Fan, Z., Clark, M., Lea, A., Luong, D., Setayesh, A., Starzinski, A., Wolters, R., Arias-Badia, M., Allaire, K., Wu, K., Gurunathan, V., Valderrábano, L., Wei, X. X., Miller, R. A., Van Allen, E. M., & Fong, L. (2025). Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. https://doi.org/10.1038/s41586-024-08290-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.